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ABSTRACT
The endothelium is the largest organ in the body and recent studies have shown that the endothelial glycocalyx (eGCX)
plays a major role in health and disease states. The integrity of eGCX is vital for homoeostasis and disruption of its
structure and function plays a major role in several pathologic conditions. An increased understanding of the numerous
pathophysiological roles of eGCX may lead to the development of potential surrogate markers for endothelial injury or
novel therapeutic targets. This review provides a state-of-the-art update on the structure and function of the eGCX,
emphasizing the current understanding of interorgan crosstalk between the eGCX and other organs that might also
contribute to the pathogenesis of kidney diseases.
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INTRODUCTION
The vascular endothelium is the largest organ in the body,
forming an interface between the bloodstream and the blood
vessel wall. It lines the inside of all blood vessels in the body.
The luminal surface of all vascular endothelial cells is covered
by the endothelial glycocalyx (eGCX), which comprises
membrane-bound negatively charged proteoglycans, glycopro-
teins, glycolipids and glycosaminoglycans [1]. It provides the
building block needed for a strong and functional vascular en-
dothelium. Over the last few years, the potential possible patho-
physiological roles of eGCX have been the focus of intense
research. Disruption or dysfunction of the eGCX has been asso-
ciated with disease states such as diabetes, chronic kidney dis-
ease (CKD), inflammatory conditions, sepsis, hypernatraemia,
hypervolaemia and ischaemia/reperfusion injury. Also, changes
in the eGCX have been associated with treatment responses
in conditions such as sepsis. In this review we summarize evi-
dence regarding the structure and function of the eGCX, alterations
of the eGCX in various diseases states and therapeutic options.
eGCX structure
The eGCX lines the luminal surface of the vascular endothe-
lium, interacting with plasma lipids and proteins [2, 3]. The
composition and dimensions, permeability and charge of the
eGCX interact dynamically with blood flow throughout the vas-
culature [4, 5]. The eGCX is attached to the endothelial cells
through several backbone molecules, mainly proteoglycans and
glycoproteins, creating a network in which soluble molecules
from either plasma or endothelium are incorporated [1].
Proteoglycans consist of a core protein that can contain one or
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more negatively charged glycosaminoglycan (GAG) side chains.
eGCX proteoglycans are structurally diverse regarding the size
of the core protein, the number and type of GAG side chains and
attachment to the endothelial cell membrane. Some core pro-
teins such as syndecan are attached to endothelial cells through
a transmembrane domain [6]. Others, such as glypican, are con-
nected to the endothelial cell membrane through a glycosylphos-
phatidylinositol anchor [7], while others, such as perlecans,
decorins, versicans, mimecans and biglycans, are secreted after
the attachment and modification of GAG side chains [1].
GAGs are characterized by distinct linear disaccharide polymers
of variable length. There are five types of GAGs: hyaluronic acid
(HA), heparan, chondroitin, keratin and dermatan sulphates.
Among these, heparan sulphate is the dominant type, making up
50–90%. Small modifications in the concentration and organization
of GAGs can have a great impact on eGCX function since GAGs con-
tain many distinct binding sites for plasma-derived proteins [1].
HA is a much longer GAG than heparan or chondroitin sulphate.
HA is secreted on the endothelial surface and linked to the endo-
thelial surface receptor CD 44 in caveolae. It weaves into the eGCX
through its interaction with the CD44 receptor. Even if it is not
sulphated, as opposed to the other four types of GAGs, it gets a neg-
ative charge from hydration properties supplied by carboxyl groups
[8]. HA has been found to provide a direct connection between the
endothelium and its extracellular matrix and is involved in the
maintenance of eGCX integrity. The loss of HA as a part of eGCX
degradation is observed to be closely associated with the endothe-
lial dysfunction, which is an early predictor of many diseases such
as diabetes, hypertension, atherosclerosis and dyslipidemia [9].
Endothelial glycoproteins also contribute to preserve eGCX
stability. Endothelial glycoproteins contain 2–15 sugar residues
arranged as branched carbohydrate side chains and comprise
adhesion molecules, such as selectins (E and P), integrins and
immunoglobulins, and some components of coagulation, hae-
mostasis and fibrinolysis. Molecules secreted by glycoproteins
participate in a wide range of eGCX functions, including endo-
thelial cell adhesion, recognition and recruitment from the
bloodstream and cell signalling [1] (Figure 1).
Functions of eGCX
eGCX functions are summarized in Table 1. Tissue fluid balance
and microvascular fluid exchange have been classically
explained by the Starling principle since 1896. However, recent
developments in our understanding of eGCX functions have in-
creased the need for revising the Starling principle by incorpo-
rating the glycocalyx model. The eGCX is also known as the
endothelial gatekeeper, summarizing its main physiological
role as being the key determinant of vascular permeability,
maintaining the balance between fluid filtration and absorption
in the capillary lumen [1, 10].
The eGCX, composed of a negatively charged network of
GAGs and proteoglycans, coats the luminal surface of the vascu-
lar endothelium. The eGCX is not permeable to large molecules
such as dextran, and its neutralization increased rat mesenteric
artery permeability for fluorescence-labelled dextrans [11]. The
negatively charged GAGs also contribute to prevent albumin
transport through the vascular wall barrier [12]. Thus vascular
permeability is modified by the molecular size, structure and
electrostatic charge of the eGCX [13].
The eGCX also modulates interactions between the vessel
wall and blood cells. The negatively charged eGCX repels and is
impermeable to red blood cells (RBCs), contributing to ensure
the enclosed flow of RBCs in the microcirculation, and weakens
the interaction of leucocytes and platelets with the vessel wall,
thus controlling platelet and leucocyte adhesion and modulat-
ing the haemostatic and inflammatory responses [1, 12, 14].
eGCX adhesion molecules, including intercellular adhesion
molecules 1 and 2, platelet/endothelial cell adhesion molecule
and vascular cell adhesion molecule (VCAM), behave as ligands
for integrins on leucocytes and platelets [1] and are induced by
the inflammation. After monocyte and neutrophil adhesion via
integrins and selectins, adhesion molecules promote cell rolling
and leucocyte extravasation [15]. On the other hand, how the
glycocalyx (conversely) inhibits leucocyte adhesion as shown by
some studies needs further investigation [16, 17].
The eGCX also controls the interaction with the microenvi-
ronment by enabling binding of ligands and enzymes that regu-
late cell signalling, enzyme modifications and vascular
protection. Without being exhaustive, fibroblast growth factors
and the lipolytic system [lipoprotein lipase and its ligand low-
density lipoprotein (LDL)] are dependent on the interactions of
their ligands and receptors within the eGCX [1]. Moreover, the
eGCX is a binding site for crucial anticoagulant mediators such
as heparin cofactor II, antithrombin III, thrombomodulin and
tissue factor pathway inhibitor (TFPI). Heparin cofactor II is a
FIGURE 1: Structure and functions of eGCX in physiological and pathological conditions.
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plasma protease inhibitor, inhibiting thrombin when in the
presence of eGCX dermatan sulphate. Antithrombin III inhibi-
tion of coagulation by lysing thrombin, factor Xa and factor IXa
is enhanced when it is bound to eGCX heparan sulphate. The
endothelial cell surface protein thrombomodulin contains GAGs
(chondroitin sulphate) and is a cofactor for thrombin. TFPI is a
single-chain polypeptide that can reversibly inhibit factors VIIa
and Xa after binding the eGCX heparan sulphates [1, 18, 19].
The eGCX may also protect the endothelium by binding
enzymes that metabolize oxygen radicals, such as extracellular
superoxide dismutase. These enzymes maintain nitric oxide
(NO) bioavailability, decrease oxidative stress and prevent endo-
thelial dysfunction [1, 18, 19]. Furthermore, the eGCX facilitates
the release of NO when exposed to shear stress, thus reducing
shear stress by dilating vessels [18–20]. Heparan sulphate pro-
teoglycans sense the shearing force of interstitial flow, resulting
in mechanotransduction and activation of specific cellular
responses [21]. Most mechanical stress is converted to biochem-
ical signals through the solid phase of the eGCX rather than
through its fluid phase. The eGCX is also able to redistribute to
perform some of its important actions, thus modulating micro-
vessel haemodynamics [22].
Disruption of the eGCX and its role in pathophysiology
The eGCX may be damaged by exposure to shear and oxidative
stress in conditions such as diabetes, sepsis, CKD, hypernatrae-
mia, hypervolaemia and ischaemia/reperfusion injury [12, 23–
27]. Here we will discuss the suspected roles of the eGCX in
these conditions.
DISEASES
Diabetes and hyperglycaemia
Diabetes mellitus (DM) may be complicated by microvascular
(retinopathy, neuropathy, nephropathy) and macrovascular
[cardiovascular disease (CVD), peripheral arterial disease,
stroke] injury. Chronic hyperglycaemia injures the vessel wall,
leading to increased endothelial permeability and impaired NO
synthase function. However, the precise cause-and-effect rela-
tionship between vascular dysfunction and DM complications
are not fully understood [7]. Shedding of the eGCX is thought to
contribute to DM-induced vascular dysfunction. Assessment
of the systemic glycocalyx volume in 10 healthy subjects by
comparing the distribution volume of a glycocalyx-permeable
tracer (dextran 40) and a glycocalyx-impermeable tracer showed
that the systemic glycocalyx volume was decreased by 50%
within 6 h after induction of acute hyperglycaemia [28].
Hyperglycaemia also increased plasma hyaluronan levels and
promoted endothelial dysfunction and coagulation activation
[28]. The eGCX thickness was 50% lower in DM patients than in
healthy controls, while serum hyaluronidase and hyaluronan
levels were higher in diabetics [23]. The thinnest eGCX was
found in DM patients with microalbuminuria [23]. Furthermore,
the eGCX volume was lower in sublingual and retinal vessels
from patients with type 2 DM [29]. Overall, these studies
revealed that both acute and chronic hyperglycaemia signifi-
cantly reduced eGCX size, supporting the idea that eGCX disrup-
tion may be associated with DM-induced endothelial
dysfunction.
Endothelial dysfunction, characterized by faulty vasodilation
due to decreased NO availability in response to endothelium-
derived relaxing factors, is present in both type 1 and 2 DM
patients. It is a well-known risk factor for CVD and is thought to
lead to microangiopathy by altering vascular permeability,
blood flow and pressure [30–39]. Indeed, endothelial dysfunc-
tion predicts early micro- and macrovascular complications of
DM. Several other mechanisms may also contribute to endothe-
lial dysfunction in DM, including dyslipidaemia and hyperten-
sion. However, hyperglycaemia itself is still thought to be the
primary cause of DM-related eGCX disruption and dysfunction
[38]. Mediators of hyperglycaemia-induced eGCX damage in-
clude reactive oxygen species, advanced glycation end products
and the activation of glycocalyx-degrading enzymes such as hy-
aluronidase (HYAL1) and heparanase [23, 38].
DM-related eGCX shedding correlated with altered serum
GAG concentrations, including increased HA, syndecan-1 and
chondroitin sulphate and decreased heparan sulphate. HA and
syndecan-1 were recently proposed as plasma markers of DM-
related eGCX shedding. Plasma syndecan-1 was increased in
both type 2 and 1 DM patients with diabetic nephropathy and
microalbuminuria. However, further studies are required to de-
termine exactly how DM-induced eGCX loss and dysfunction
contributes to vascular injury and dysfunction in DM [38].
Sepsis
Sepsis is a systemic inflammatory response to a documented or
presumed infection. The eGCX is damaged early in the course of
inflammatory conditions such as systemic inflammatory re-
sponse syndrome and sepsis. In hamsters, tumour necrosis fac-
tor-a (TNF-a), a representative pro-inflammatory cytokine,
damaged the eGCX and enhanced macromolecular permeability
without increasing leucocyte recruitment [40]. TNF-a induced
release of cytokines, heparinase and histamine and proteases
by mast cells further disrupted the eGCX [41]. TNF-a induced
shedding of syndecan-4 were mediated by matrix metallopro-
teinase-9 (MMP-9), contributing to eGCX damage [42]. There is
also evidence that endothelial signalling is critical to septic gly-
cocalyx degradation via TNF-a [17, 43].
Increased serum eGCX constituent levels correlated with in-
creased mortality in sepsis [41, 44]. Shedding of eGCX constitu-
ents, such as endothelial cell adhesion molecules, is thought to
induce further inflammation and increase recruitment of leuco-
cytes and platelets contributing to organ dysfunction, such as
acute kidney injury (AKI) and respiratory failure [45, 46].
Disruption of the eGCX in sepsis is associated with increased
vascular wall permeability to macromolecules, loss of circulat-
ing albumin and subsequent fluid extravasation and oedema
Table 1. Functions of eGCX
Acts as the exclusion zone between blood cells and the endothelium
The exact composition varies greatly according to the local
microenvironment
Plays the main role in transvascular fluid exchange and fluid balance
(acts as the ‘molecular sieve’ for plasma proteins, forming the ba-
sis of the Starling principle and acting as the origin of the oncotic
forces, which control the transcapillary movement of water)
Modulates adhesion of inflammatory cells and platelets to the endo-
thelial surface
Functions as a sensor and mechanotransducer of the fluid shear
forces
Maintains blood rheology and damage leads to platelet activation
(normally retains anticoagulation factors such as antithrombin)
Plays a role in shear stress–dependent nitric oxide production
Retains protective enzymes (e.g. superoxide dismutase)
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[7]. Parenteral albumin did not increase survival rates in sepsis
patients as compared with crystalloids alone [47]. Together,
these studies suggest that while eGCX disruption persists, effec-
tive oncotic pressure cannot be restored by administering albu-
min since large amounts of albumin will continue to leak into
the interstitial space [48].
CVD
Despite therapeutic efforts to tackle the main risk factors (dysli-
pidaemia, high blood pressure, diabetes, obesity, smoking), CVD
remains the leading cause of death globally. Atherosclerosis is a
major cause of CVD and dysfunction of vasculo-protective en-
dothelium is a key contributor. Exploration of the vasculo-pro-
tective properties of the vessel wall against atherosclerosis may
identify novel therapeutic approaches [49]. The eGCX is consid-
ered to be protective from atherosclerosis, and eGCX shedding
is associated with loss of the vasculo-protective properties of
the vessel wall [49]. eGCX shedding increases lipid fluxes that
lead to lipid deposition in the vessel wall, a characteristic fea-
ture of atherosclerosis, interferes with endothelial cell commu-
nication and increases inflammatory cell migration to the
vessel wall. Thus disruption of the eGCX leads to decreased en-
dothelial NO synthase expression by endothelial cells, promot-
ing vasoconstriction and dysregulation of vascular tone.
Emerging eGCX-targeted approaches could potentially be used
to restore eGCX and treat early cases of atherosclerosis [50].
In isolated pig heart, near-complete eGCX shedding occurred
after reperfusion following 20 min of warm (37C) no-flow is-
chaemia, resulting in increased capillary permeability-induced
tissue oedema with enhanced coronary perfusion pressure [51].
These results are consistent with human findings of increased
plasma levels of eGCX constituents following coronary artery
bypass or peripheral arterial surgery [45]. In pig heart, anti-
thrombin significantly decreased post-ischaemic eGCX shed-
ding, vascular leakage/tissue oedema and coronary perfusion
pressure. Protection by antithrombin was potentiated by the ad-
dition of colloid [51].
Statins are the most used lipid-lowering medications, reduc-
ing LDL cholesterol through inhibition of 3-hydroxy-3-methyl-
glutaryl-coenzyme A (HMG-CoA) reductase. Statins have
pleiotropic actions beyond lowering LDL cholesterol, which de-
pend on inhibition of intracellular signalling requiring HMG-
CoA reductase metabolites, such as inflammatory cytokine-
induced signalling in endothelial cells, a key driver of eGCX
shedding [9]. Additionally, familial hypercholesterolaemia is
associated with a profound perturbation of the eGCX.
Rosuvastatin for 8 weeks led to the partial recovery of systemic
glycocalyx volume in 13 patients with heterozygous familial
hypercholesterolaemia [52]. However, uncertainty still exists
about whether this is related to a direct statin effect or to im-
proved lipid status [45].
Diazoxide is a potassium channel activator with antihyper-
tensive and hyperglycaemic activities. During coronary artery
bypass surgery, diazoxide decreased post-surgical plasma hya-
luronan and syndecan-1 levels, which supported the idea that
diazoxide treatment may reduce disruption of the eGCX [53].
Oxidative stress is widely recognized as a major contributor
to the development of endothelial dysfunction, eGCX disruption
and atherosclerosis progression. In experimental metabolic
syndrome, combination therapy with olmesartan and azelnidi-
pine successfully reduced oxidative stress via inhibition of nico-
tinamide adenine dinucleotide phosphate oxidase activity in
aortic endothelial cells and improved endothelial function and
maintenance of eGCX integrity [54].
CKD
Intact endothelial cell function is essential for normal kidney
function. Patients with CKD have increased eGCX shedding,
which is associated with endothelial dysfunction. Plasma levels
of two major eGCX components, syndecan-1 and hyaluronan,
increased steadily across CKD categories [25]. This is thought to
be a consequence of increased shedding, although a lack of uri-
nary excretion of immune reactive degradation products could
not be entirely ruled out. Supporting the increased shedding hy-
pothesis, plasma syndecan-1 and HA positively correlated with
plasma markers of endothelial dysfunction such as von
Willebrand factor, soluble fms-like tyrosine kinase-1, angiopoie-
tin-2 and soluble vascular adhesion molecule-1. Consistently, in
a rat model of CKD, plasma syndecan-1 inversely correlated
with eGCX thickness, which was significantly decreased in aor-
tic endothelial cells from CKD rats [27]. Overall, this study sug-
gests that eGCX integrity and function are compromised in
CKD. However, the specific mechanisms underlying the loss of
eGCX integrity in CKD are not yet fully understood. In CKD, en-
dothelial dysfunction is widely acknowledged to be a risk factor
for atherosclerosis and cardiovascular events [55, 56]. Further
supporting the causative link between CKD and endothelial dys-
function, endothelial function improves after kidney transplan-
tation [55, 57, 58].
To investigate the association between renal function and
the eGCX dimension, the perfused boundary region (PBR) was
measured in control participants, patients with normal kidney
function after kidney transplantation, end-stage renal disease
patients and patients with interstitial fibrosis/tubular atrophy
by using non-invasive sidestream darkfield (SDF) imaging.
Serum levels of eGCX components such as syndecan-1, soluble
thrombomodulin and the marker of endothelial activation,
angiopoietin-2, were also measured [51]. This study indicated
that PBR and the serum levels of sydecan-1 and thrombomodu-
lin were elevated in patients with end-stage renal disease or in-
terstitial fibrosis/tubular atrophy compared with the control
participants and stable kidney transplant patients. PBR was also
found to be positively correlated with angiopoietin-2. Taken to-
gether, these results support the idea that patients with reduced
renal function (estimated glomerular filtration rate) have a de-
creased eGCX dimension [59]. Although diabetic nephropathy
induces a decrease in eGCX dimension [60], the link between
eGCX and end-stage renal disease is still not fully understood.
Oltean et al. [61] demonstrated in a mouse study that vascular
endothelial growth factor-A (VEGF-A) played a key role in renal
endothelial dysfunction. In a murine diabetic nephropathy
model, kidney VEGF-A165b was upregulated in mice without a
loss of kidney function but not in those with a loss of kidney
function. The VEGF-A165b isoform was shown to be involved in
the phosphorylation of VEGF receptor 2 on the glomerular endo-
thelial cells, reducing the degree of diabetic nephropathy
vascular endothelial growth factor related eGCx damage and
improving glomerular permeability. After observing the func-
tional and histologic benefits of administration of VEGF-A165b
in animal models with diabetic nephropathy, VEGF-A165b was
tested on isolated diabetic human glomeruli. The permeability
function of the human glomeruli was also restored with the ad-
ministration of VEGF-A165b, protecting the eGCx of renal vascu-
lature from the destructive effects of diabetic nephropathy [61].
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Inflammation contributes to eGCx damage during kidney
disease. Monocyte chemotactic protein-1 [MCP-1/chemokine (C-
C motif) ligand 2] is the key chemokine recruiting inflammatory
cells such as monocytes and macrophages to the kidney and
clinical trials targeting MCP-1 support its pathogenic role in
humans [62]. Inhibition of MCP-1 with emapticap pegol (NOX-
E36) restored the eGCx barrier dimensions in streptozotocin-
induced diabetes in Apoe knockout mice. NOX-E36 decreased
eGCx degradation by heparinase, which was regulated by
macrophage-secreted cathepsin L. This was associated with de-
creased albuminuria and kidney inflammation in the absence
of changes in systemic haemodynamics [63]. Atrasentan, a se-
lective endothelin A receptor antagonist whose clinical trial for
diabetic nephropathy was recently terminated, decreased albu-
minuria by repairing the eGCX barrier in patients with diabetic
nephropathy [64].
Evidence of eGCX degradation was also observed in patients
suffering from ischaemia/reperfusion injury during vascular
surgery [65]. In another study, ischaemic AKI in renal transplan-
tation from donors after cardiac death (DCD) and living donors
was investigated by using SDF imaging of peritubular capillaries
and serum levels of syndecan-1 and heparan sulphate. DCD kid-
neys were reported to have reduced capillary flow and higher
serum levels of syndecan-1 and heparan sulphate compared
with living donor kidneys with minimal ischaemia. These find-
ings provided strong evidence that the eGCx was degraded due
to ischaemia and subsequent reperfusion. The loss of endothe-
lial cells and eGCX integrity could contribute to AKI through de-
creasing tissue perfusion and more inflammation following
reperfusion [66].
Administration of GAG-degrading enzymes (hyaluronidase,
heparinase and chondroitinase) to mice resulted in increased
glomerular vascular permeability to albumin but not to Ficoll
(uncharged polymer), indicating that eGCX degradation led to
reduced charge selectivity and proteinuria [67]. These results
support a role for eGCX damage and systemic endothelial dys-
function in the genesis of albuminuria [68].
Plasma syndecan-1 and HA levels were higher in dialysis
patients than in controls, showing that dialysis patients lost
eGCx barrier functions and the severity of the loss was corre-
lated with the level of inflammation. The authors also mea-
sured the eGCx dimension using the PBR and checked the
serum markers of the eGCX components and endothelial dys-
function, such as E-selectin. Interestingly, no correlation was
detected between the variables [26].
Peritoneal dialysis requires a healthy peritoneal membrane.
It is thought that both a healthy mesothelium and peritoneal
vessels are required to preserve the peritoneal barrier. In perito-
neal dialysis patients, SDF imaging of the sublingual microvas-
culature did not disclose any relationship between PBR
assessment of systemic eGCx and peritoneal transport parame-
ters [69]. This is not surprising, given that peritoneal vessels re-
ceive the bulk of the peritoneal fluid bio-incompatibility
challenge [70]. Thus some of the most toxic and highly reactive
peritoneal dialysis fluid metabolites, such as 3,4-dideoxygluco-
sone-3-ene readily react with peritoneal membrane compo-
nents and do not reach the systemic circulation [71].
MOLECULES
Albumin
Albumin is the major serum protein and has multiple important
functions. Stabilization of eGCX is thought to be one of them.
Electrostatic interactions occur between negatively charged
GAGs in the eGCX and the positively charged arginine in albu-
min. It is believed that hypoalbuminaemia could facilitate shed-
ding of the eGCX [72].
Albumin transports multiple small molecules, including free
fatty acids and spingosine-1-phosphate (S1P) [73]. Binding of
S1P to its receptors resulted in MMP inhibition and eGCX integ-
rity preservation [74]. In this regard, in trauma patients, higher
plasma levels of syndecan-1, a sign of eGCX shedding, was sig-
nificantly correlated with a reduction in plasma colloid osmotic
pressure [75]. However, this study sheds no light on whether
hypoalbuminaemia facilitated eGCX shedding or eGCX shed-
ding promoted hypoalbuminaemia.
In a recent study, Garsen et al. [76] showed that endothelin-1
induces proteinuria by heparanase-mediated disruption of the
glomerular glycocalyx in diabetic nephropathy. In this study,
the authors demonstrated that in mice, podocyte-specific
knockout of the endothelin receptor prevented the diabetes-
induced increase in glomerular heparanase expression, conse-
quent reduction in heparan sulphate expression and eGCX
thickness and development of proteinuria observed in wild-
type counterparts [76].
Thus the relationship between albumin and eGCX seems to
be reciprocal. eGCX disruption may facilitate albumin transloca-
tion to the interstitial space, while hypoalbuminaemia itself
may disturb the function and structure of the eGCX.
Glomerular endothelium, glomerular basement membrane
and podocytes are the three key components of the glomerular
filtration barrier (GFB). Pathological albuminuria results from in-
creased passage of albumin through the GFB, which exceeds the
capacity of proximal tubular cells to reabsorb albumin.
Pathological albuminuria is an important indicator of glomeru-
lar filtration dysfunction and, as an early sign of progressive
cardiovascular and renal disease, is considered as a criterion to
diagnose CKD [77]. While classically considered a marker of
podocyte injury, albuminuria has been observed in the absence
of podocyte changes, confirming the close integration of GFB
components and the potential impact of endothelium and base-
ment membrane injury on glomerular albumin permeability.
The endothelial surface layer, comprised of the eGCX and
adsorbed plasma constituents, restricts the permeability of glo-
merular capillaries to albumin. Communication between
the glomerular endothelium and podocytes also influenced the
contribution of podocytes to the albumin permeability of the
GFB [78].
Recently a novel sensitive glomerular permeability assay
confirmed that eGCX damage leads to increased albumin glo-
merular permeability in a mouse model. eGCX dysfunction in
diabetic mice was associated with increased urinary albumin
excretion. Furthermore, eGCX function was restored by angio-
poietin-1 [79]. Patients with albuminuric CKD had widespread
loss of the eGCX, which was hypothesized to lead to increased
systemic microvascular permeability, linking albuminuria to
systemic vascular disease [78, 80].
Tissue sodium deposition
High salt (NaCl) intake has a blood pressure–independent effect
on endothelial function, contributing to the development of
vascular diseases, whereas the arterial system benefits from
lowering salt intake. The eGCX has been proposed as an effec-
tive sodium buffer since positively charged sodium ions can be
trapped in the eGCX mesh by negatively charged proteoglycans
[81, 82]. Quantitative eGCX analyses showed that chronic
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exposure to high ambient sodium weakened the sodium buffer
capacity of eGCX, leading to eGCX disruption through reduction
of negatively charged heparan sulphate residues [24]. High so-
dium levels increase the expression of endothelial sodium
channels (EnNaCs) in the plasma membrane. Both the collapse
of the eGCX and the increased number of EnNaCs allowed so-
dium to access endothelial cells more freely. Enhanced sodium
fluxes into endothelial cells triggers intracellular signalling that
may promote endothelial dysfunction through a reduction in
NO release and an increase in mechanical arterial stiffness [24,
83, 84]. Arterial stiffness is a well-characterized contributor to
the vasculopathy of CKD [85].
Volume
Volume loading is a blood-sparing procedure commonly used to
improve haemodynamics and optimize cardiac output.
However, it may lead to adverse effects such as tissue oedema,
hypervolaemia, hypertension and heart failure [86].
Hypervolaemia is associated with enhanced release of atrial na-
triuretic peptide (ANP) and with eGCX collapse [87]. ANP itself
was found to disrupt the eGCX through a cyclic guanosine
monophosphate–linked proteolytic pathway in patients having
coronary bypass surgery [88, 89]. Collapse of the eGCX was asso-
ciated with detrimental interstitial fluid shifting [86]. From that
perspective, plasma levels of eGCX degradation components
should be explored for their potential as surrogate markers to
assess vascular endothelial injury that may provide information
about when to limit uncontrolled fluid resuscitation to prevent
interstitial oedema [90].
Furthermore, crystalloids and colloids are the two main
types of volume expanders. Research indicates that eGCX has
an important role in the differential effects of colloids and crys-
talloids on plasma volume expansion. Crystalloid was consid-
ered to be expanded throughout the intravascular space,
whereas colloids had no ability to distribute into the glycocalyx
[91–93]. This issue is important since, during fluid resuscitation,
the integrity of the eGCX should be considered. For example, re-
cent studies have shown that crystalloid versus colloid infusion
makes sense when considering the integrity of the eGCX in criti-
cal patients [92, 93].
THERAPEUTIC RESTORATION OF THE EGCX
The eGCX may restore itself within 5–7 days of an insult [94].
Accelerating restoration of the eGCX and protecting it from fur-
ther damage are promising targets for the treatment of chronic
vascular disease, as well as management of patients in critical
care settings [44]. To date, there is no established drug directly
acting on protection and regeneration of the eGCX [95].
However, some agents have been explored in this regard, in-
cluding sulodexide, albumin, fresh frozen plasma, glucocorti-
coids and other agents.
Sulodexide is a mixture of heparin sulphate (80%) and der-
matan sulphate (20%) extracted from porcine intestinal mucosa
that has been unsuccessfully tested in clinical trials for diabetic
nephropathy, but is in clinical use for venous insufficiency [96].
In type 2 diabetic patients, sulodexide restored the components
of the eGCX in the retinal circulation within 8 weeks [29]. In rats
with carotid artery balloon injury, sulodexide restored the eGCX
and reduced damage, blood coagulation, lipid metabolism and
local inflammation [97]. Sulodexide also accelerated eGCX resto-
ration, decreased vascular permeability and increased survival
in septic mice [98].
Albumin and fresh frozen plasma have several clinical
indications. In pig heart transplantation–induced ischaemia/
reperfusion, albumin decreased interstitial oedema and leucocyte-
to-endothelial interaction within coronary arteries, contributing
to preserve eGCX integrity [99]. Albumin is a carrier for several bio-
active molecules, including S1P [100]. S1P is considered to protect
the eGCX by inhibiting syndecan-1 shedding [101].
Fresh frozen plasma also protects eGCX integrity and pre-
serves syndecan-1. In addition to being a source of albumin,
fresh frozen plasma may inhibit various proteases that disrupt
the eGCX and may induce the release of preformed syndecan-1
from endothelial cells [102].
Glucocorticoids are widely used as anti-inflammatory
agents. They preserve the eGCX precisely through anti-
inflammatory actions on leucocytes and by reducing cytokine-
induced damage on the vascular barrier [103]. In an isolated pig
heart model, administration of hydrocortisone protected the
eGCX against ischaemia/reperfusion and TNF-a infusion [104].
A better characterization of the molecular basis of these effects
may reveal new cellular targets for drug development devoid of
the extensive adverse effects profile of glucocorticoids.
Several additional approaches have preserved eGCX volume
in animal studies, including NO, TNF-a inhibitors, hyaluronan,
TNF–polyethylene glycol, allopurinol, adenosine agonists and
heparin [7].
CONCLUSION
Damage to the eGCx during DM and other systemic diseases
appears to be a key contributor to endothelial dysfunction.
Additional identification of factors regulating the stability and
repair of the eGCx under stress conditions and the pathophysio-
logical roles of the eGCx might ultimately lead to the design of
new diagnostic and therapeutic strategies for diseases charac-
terized by endothelial dysfunction or vascular injury, including
CKD.
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